Thus, the results of g3mclass data analyses show the accuracy of identifying breast cancer potentially sensitive to anti-HER2 therapy and the robustness of the software in making the correct classification without equivocal results in the test and independent query. The gene discussed is ERBB2; the disease is breast cancer.